Navigation Links
Preclinical study of a new brain tumor therapy

Scientists have devised a strategy to treat tumors by selectively targeting and killing the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM). This is the most aggressive form of brain tumour, growing very quickly before symptoms are experienced and killing most patients within a year of diagnosis.

Working in mice, Alexander Levitzki and colleagues (of The Hebrew University of Jerusalem and Ludwig-Maximilians-University in Munich) took advantage of previous research that showed how to distinguish between cancerous and healthy cells through the detection of molecules known as epidermal growth factor receptors (EGFR). The glioblastoma cells overexpress EGFR (that is, in comparison with normal brain cells, they have many more of these molecules on their surface). The scientists then selected a type of genetic material (a nucleic acid) associated with viral infections and linked it to a compound that could bind to EGFR. As a result of the defence mechanisms that have evolved to protect mammalian cells from viruses, cells are programmed to die once they take up this particular nucleic acid. The treatment therefore eliminates the tumor cells but avoids damage to the normal brain tissue.

The researchers found that the treatment was effective in mice implanted with human brain tumor cells that overexpressed EGFR. The treatment could eliminate established cancers and there was no evidence of recurrence: the mice remained cancer free for over a year. It is more difficult to cure cancer in humans than cancer in mice, but the results are encouraging. In his Perspective article accompanying the study, Robert Weil of the Brain Tumor Institute at the Cleveland Clinic Foundation suggests that the approach deserves to be "fast-tracked to the clinic" given the lack of effective treatments for GBM. There are few existing options aside from chemotherapy and surg ery to remove the tumor, and it is rare that these treatments stop the cancer from recurring. Given the prevalence of EGFR in cells of other cancer types (such as breast cancer and lung cancer), the approach pioneered in this study may be applicable to other forms of cancer as well.


'"/>

Source:Public Library of Science


Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
(Date:11/14/2016)... Calif. , Nov. 14, 2016 /PRNewswire/ ... biometric identification market, Frost & Sullivan recognizes ... & Sullivan Award for Visionary Innovation Leadership. ... in the biometric identification market by pioneering ... verification solution for instant, seamless, and non-invasive ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... 30, 2016  GenomOncology today announced the appointment of ... Affairs.  Dr. Coleman will oversee clinical content ... knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with ... and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... , Nov. 30, 2016  The Allen ... Cell Collection: the first publicly available collection of ... cells that target key cellular structures with unprecedented ... Research, these powerful tools are a crucial first ... to better understand what makes human cells healthy ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... ... November 30, 2016 , ... Energetiq Technology, a world leader ... generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at the MRS Fall Exhibit 2016. ... offers higher radiance and irradiance from a truly broadband white light source. The ...
Breaking Biology Technology: